Study of the Role of PCSK9 and FXR in the Physiopathology of the Joint Dyslipidemia Associated to the Human Immunoresistance

StatusCompleted
PhaseNot applicable
Started

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Track this trial
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Publications: 1 to 2v9
  2. Trial status: Active, Not Recruiting to Completed
    • Primary and study completion dates changed from estimate of Oct 2013 to Nov 2013
    v8
  3. Primary and study completion dates: Dec 2012 to Oct 2013v7 Show 4 more changesShow less
    • Start date: Feb 2007 to Feb 2008
    • Trial status: Recruiting to Active, Not Recruiting
    • Enrollment target: estimated 120 to confirmed 111
    • Site details revised
  4. 2 versions Re-verified since Aug 26, 2011, no change to tracked fieldsv5-v6
  5. Primary and study completion dates: Dec 2012
    • Interventions: biopsies for biological and genetic analyses (Other), biopsy of muscle, of liver, and of adipose tissue (Procedure), clamp… to biopsies for biological and genetic analyses (Other), biopsy of muscle, of liver, and of adipose tissue (Procedure), clamp euglycemic…
    • Eligibility criteria revised
    v4
Show 2 earlier versionsHide 2 earlier versions
  1. Re-verified, no change to tracked fieldsv3
  2. Trial status: Not Yet Recruiting to Recruitingv2 Show 5 more changesShow less
    • Enrollment target: 120
    • Study sites: 0 to 1
    • Interventions: biopsy of muscle, of liver, and of adipopse tissue (Procedure), clamp euglycemical-hyperglycemical (Procedure), diet (Behavioral) to biopsies for biological and genetic analyses (Other), biopsy of muscle, of liver, and of adipose tissue (Procedure), clamp…
    • Study arms: 0 to 4
    • Eligibility criteria expanded, about 2 words
  1. Study First Submitted
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Experimental results are strongly suggesting that PCSK9 and FXR could occur in the physiopathology of human joined dyslipidemia. But no data in the literature can validate the potential role of these two genes in the lipidic and glucidic metabolism control in physiopathological situations. This protocol is based on the hypothesis that the expression levels of PCSK 9 and FXR are modified for some patients suffering from insulin resistance and dyslipidemia.
Trial Details
NCT Number NCT00422006
Lead Sponsor Nantes University Hospital
Conditions
(from sponsor)		 Obesity
Related terms Obesity
Enrollment 111 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov